Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis.

Xie F, Yan L, Lu J, Zheng T, Shi C, Ying J, Shen R, Yang J.

PLoS One. 2013;8(1):e54773. doi: 10.1371/journal.pone.0054773. Epub 2013 Jan 28.

2.
3.

Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.

Su QM, Ye XG.

World J Gastroenterol. 2012 Nov 21;18(43):6290-301. doi: 10.3748/wjg.v18.i43.6290. Review.

4.

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E.

Gastroenterology. 2014 Apr;146(4):980-8. doi: 10.1053/j.gastro.2013.12.028. Epub 2013 Dec 22.

PMID:
24368224
5.

Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.

Li CZ, Hu JJ, Xue JY, Yin W, Liu YY, Fan WH, Xu H, Liang XS.

World J Gastroenterol. 2014 Jul 28;20(28):9486-96. doi: 10.3748/wjg.v20.i28.9486.

6.

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.

Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA; 018 Study Group.

Ann Intern Med. 2007 Dec 4;147(11):745-54. Epub 2007 Oct 1.

PMID:
17909201
7.

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F.

N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.

8.

Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.

Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.

Antivir Ther. 2013;18(4):623-33. doi: 10.3851/IMP2555. Epub 2013 Mar 13.

PMID:
23486701
9.

The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis.

Zhang X, Liu L, Zhang M, Gao S, Du Y, An Y, Chen S.

Ann Hepatol. 2015 Mar-Apr;14(2):150-60. Review.

11.

Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.

Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH.

World J Gastroenterol. 2012 Dec 21;18(47):6996-7002. doi: 10.3748/wjg.v18.i47.6996.

12.

Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.

Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J.

Hepatology. 2009 Jan;49(1):72-9. doi: 10.1002/hep.22658.

PMID:
19065670
13.

On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.

Huang YW, Takahashi S, Tsuge M, Chen CL, Wang TC, Abe H, Hu JT, Chen DS, Yang SS, Chayama K, Kao JH.

Antivir Ther. 2015;20(4):369-75. doi: 10.3851/IMP2777. Epub 2014 Apr 16.

PMID:
24739420
14.

Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.

Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lau G, Lee S, Gane EJ.

Gastroenterology. 2014 May;146(5):1240-8. doi: 10.1053/j.gastro.2014.01.044. Epub 2014 Jan 23. Erratum in: Gastroenterology. 2015 Jan;148(1):263. Lau, George [added].

PMID:
24462735
15.

Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment.

Kozielewicz D, Halota W, Wietlicka-Piszcz M.

Hepatol Int. 2016 Mar;10(2):302-9. doi: 10.1007/s12072-015-9681-6. Epub 2015 Nov 26.

16.

Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.

Peng H, Liu J, Yang M, Tong S, Yin W, Tang H, Hu P, Hu H, Ren H.

J Clin Pharmacol. 2014 Feb;54(2):189-200. doi: 10.1002/jcph.181. Epub 2013 Oct 4.

PMID:
24105676
17.

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.

Jung SK, Kim KA, Ha SY, Lee HK, Kim YD, Lee BH, Paik WH, Kim JW, Bae WK, Kim NH, Lee JS, Jwa YJ.

Clin Mol Hepatol. 2015 Mar;21(1):41-8. doi: 10.3350/cmh.2015.21.1.41. Epub 2015 Mar 25.

18.

Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.

Chaung KT, O'Brien C, Ha NB, Nguyen NH, Trinh HN, Nguyen MH.

J Clin Gastroenterol. 2016 Apr;50(4):338-44. doi: 10.1097/MCG.0000000000000455.

PMID:
26646801
19.

Treatment of chronic hepatitis B: Evolution over two decades.

Yuen MF, Lai CL.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:138-43. doi: 10.1111/j.1440-1746.2010.06545.x. Review.

PMID:
21199525
20.

Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.

Pan CQ, Chan S, Trinh H, Yao A, Bae H, Lou L.

World J Gastroenterol. 2015 May 14;21(18):5524-31. doi: 10.3748/wjg.v21.i18.5524.

Supplemental Content

Support Center